Iradimed (IRMD) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Roth MKM | Maintained | Buy | $72.00 from $60.00 | Feb 14, 2025 |
| Roth MKM | Maintained | Buy | $60.00 from $65.00 | Aug 2, 2024 |
| Roth MKM | Maintained | Buy | $65.00 | Apr 22, 2024 |
Frequently asked questions
Is IRMD a buy, sell, or hold?
Analysts covering Iradimed currently average a Buy rating: 2 buy, 0 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on IRMD?
On Feb 14, 2025, Roth MKM maintained Iradimed at Buy with a price target of $72.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.